National Comprehensive Cancer Network


Previous NCCN Trends™ Survey Data

Reviewing data from previous NCCN Trends™ Surveys provides insight into various past topics which can assist in developing future NCCN Trends™ Surveys for your organization.

The Summary Reports for previous NCCN Trends™ Surveys are listed below in reverse chronological order, by subject/tumor type and are available for review prior to purchasing the Complex Report. The complex reports include the questions represented within the summary report, further analyzed by geography, practice setting, practice size, and specialty. To view a sample complex report, click here.


Acute Leukemia

July 2012 View Summary Report $2,000.00

Basal Cell Carcinoma

November 2013 View Summary Report $5,000.00

Biomarkers

October 2013 View Summary Report $5,000.00
August 2012 View Summary Report $2,000.00
June 2012 View Summary Report $2,000.00
June 2011 View Summary Report $2,000.00

Breast Cancer

February 2014 View Summary Report $5,000.00
February 2013 View Summary Report $2,000.00
November 2012 View Summary Report $2,000.00
February 2012 View Summary Report $2,000.00
December 2011 View Summary Report $2,000.00
October 2011 View Summary Report $2,000.00
August 2011 View Summary Report $2,000.00
June 2011 View Summary Report $2,000.00

Breast Cancer Assays

November 2012 View Summary Report $2,000.00
January 2012 View Summary Report $2,000.00

Cancer Anorexia Cachexia

September 2013 View Summary Report $5,000.00

Central Nervous System Lymphomas

April 2012 View Summary Report $2,000.00

Chronic Lymphocytic Leukemia

December 2013 View Summary Report $5,000.00

Chronic Myelogenous Leukemia

March 2013 View Summary Report $2,000.00
October 2012 View Summary Report $2,000.00
August 2012 View Summary Report $2,000.00

Colon Cancer

July 2012 View Summary Report $2,000.00
April 2012 View Summary Report $2,000.00

Colorectal Cancer
(Note: Metastatic Colorectal Cancer Listed Below)

June 2013 View Summary Report $2,000.00
October 2011 View Summary Report $2,000.00

DCIS

September 2012 View Summary Report $2,000.00

Drug Treatment Plans

March 2014 View Summary Report $5,000.00

GIST

March 2012 View Summary Report $2,000.00

Granulocyte-Colony Stimulating Factor

August 2013 View Summary Report $5,000.00

Hematologic Malignancies

July 2011 View Summary Report $2,000.00

Kidney Cancer

September 2011 View Summary Report $2,000.00

Liver Cancer

March 2014 View Summary Report $5,000.00

Mantle Cell Lymphoma

September 2013 View Summary Report $5,000.00

Melanoma
(Note: Metastatic Melanoma Listed Below)

October 2011 View Summary Report $2,000.00

Metastatic Breast Cancer

January 2014 View Summary Report $5,000.00

Metastatic Colorectal Cancer

June 2013 View Summary Report $2,000.00
June 2012 View Summary Report $2,000.00

Metastatic Melanoma

December 2013 View Summary Report $5,000.00
May 2013 View Summary Report $2,000.00

Multiple Myeloma

April 2013 View Summary Report $2,000.00
January 2013 View Summary Report $2,000.00
May 2012 View Summary Report $2,000.00

Myelosuppressive Chemotherapy

December 2012 View Summary Report $2,000.00

Non-Hodgkin's Lymphomas

September 2012 View Summary Report $2,000.00
September 2011 View Summary Report $2,000.00

Non-Small Cell Lung Cancer

November 2013 View Summary Report $5,000.00
October 2013 View Summary Report $5,000.00
April 2013 View Summary Report $2,000.00
January 2013 View Summary Report $2,000.00
December 2012 View Summary Report $2,000.00

Oral Cancer Agents

December 2013 View Summary Report $5,000.00

Prostate Cancer

March 2014 View Summary Report $5,000.00
July 2013 View Summary Report $5,000.00
February 2013 View Summary Report $2,000.00
September 2012 View Summary Report $2,000.00
April 2012 View Summary Report $2,000.00

Reimbursement

October 2012 View Summary Report $2,000.00

Renal Cell Carcinoma

February 2013 View Summary Report $2,000.00

Targeted Therapies

March 2012 View Summary Report $2,000.00

Note: NCCN Trends Surveys, Data and Reports are solely for internal organizational use. All NCCN Trends™ Surveys content and resulting data are owned by NCCN. Survey responses are kept anonymous to protect the privacy of survey respondents. NCCN may license survey content, data, and analytic results to third parties, but retains the rights to use this data for other purposes, including the support of educational and research efforts, and for other strategic or business purposes.

Questions must be clinical or policy related in nature and not promotional, which includes but is not limited to, company names, specific initiatives, or questions that market to the Trends audience. Final questions for distribution are at the discretion of NCCN.